(NASDAQ: CLDX) Celldex Therapeutics's forecast annual revenue growth rate of 85.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Celldex Therapeutics's revenue in 2025 is $7,020,000.On average, 3 Wall Street analysts forecast CLDX's revenue for 2025 to be $486,792,486, with the lowest CLDX revenue forecast at $278,812,006, and the highest CLDX revenue forecast at $796,605,732. On average, 2 Wall Street analysts forecast CLDX's revenue for 2026 to be $537,708,869, with the lowest CLDX revenue forecast at $278,812,006, and the highest CLDX revenue forecast at $796,605,732.
In 2027, CLDX is forecast to generate $3,323,505,498 in revenue, with the lowest revenue forecast at $1,752,532,610 and the highest revenue forecast at $5,901,520,798.